Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study 21-04-2023, 03:01

GlucoTonic Reviews (DOCTOR INVESTIGATED): Is This Blood Sugar Breakthrough the Real Deal or Dangerous Hype 2-04-2025, 09:46

EEX and Nasdaq Commodities Announce Intention to Transfer Nasdaq’s European Power Business to EEX 20-06-2023, 15:15